Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
04/09/2026 20:44
BRIEF-US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation Sept 4 (Reuters) - FDA:
US FDA - GRANTS ACCELERATED APPROVAL TO ETCAMAH FOR ADVANCED BREAST CANCER WITH ESR1 MUTATION
US FDA - AUTHORIZES GUARDANT360 CDX ASSAY AS COMPANION DIAGNOSTIC FOR BREAST CANCER
Further company coverage: AZN.L
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines